IP Library Granted Patent US 8,101,163
Granted Patent B2
US 8,101,163 · App. 12/630,690 · Granted Jan 24, 2012

Transdermal compositions

Assignee: Microdermis Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,101,163
App. No.
12/630,690
Granted
Jan 24, 2012
Kind
B2
Abstract

The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C 1 -C 6 dialkyl, C 12 -C 30 dialkyl quaternary ammonium salt, a C 12 -C 30 fatty acid, a nitrogenous organic base, C 12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Claims (87)

1. A compound having the formula

wherein R 100 is fatty groups having 11-29 carbon atoms and R 101 and R 102 are independently a fatty group having 12-30 carbon atoms.

2. The compound according to claim 1 wherein R 100 , R 102 , and R 101 independently contain 16-22 carbon atoms.

3. A carrier composition comprising the compound of claim 1 .

4. A carrier composition comprising the compound of claim 2 .

5. A method for enhancing the penetration of a drug through the skin of a mammal which comprises mixing the drug with a skin penetrating effective amount of the compound of the formula

wherein R 100 is fatty groups having 11-29 carbon atoms and R 101 and R 102 are independently a fatty group having 12-30 carbon atoms.

6. A compound having the formula selected from the group consisting of

wherein R 100 is fatty groups having 11-29 carbon atoms and R 101 and R 102 are independently a fatty group having 12-30 carbon atoms admixed with a quaternary ammonium salt of the formula

wherein R 5 , R 6 , R 9 and R 10 are independently lower alkyl, fatty group, aryl lower alkyl or R 7 wherein at least one of R 5 , R 6 , R 9 and R 10 is a fatty group, each of said fatty group containing 11-29 carbon atoms and may be completely saturated or contain 1-8 carbon-carbon double bonds,

R 7 is

R 1 —Ar—O—R 2 —O—R 3 —;

R 1 is alkyl containing 1-15 carbon atoms,

R 2 and R 3 are independently lower alkylene, and

X is a counter ion.

7. A carrier composition comprising a compound having the formula selected from the group consisting of

wherein R 100 is fatty groups having 11-29 carbon atoms and R 101 and R 102 are independently a fatty group having 12-30 carbon atoms admixed with a quaternary ammonium salt of the formula

wherein R 5 , R 6 , R 9 and R 10 are independently lower alkyl, fatty group, aryl lower alkyl or R 7 wherein at least one of R 5 , R 6 , R 9 and R 10 is a fatty group, each of said fatty group containing 11-29 carbon atoms and may be completely saturated or contain 1-8 carbon-carbon double bonds,

R 7 is

R 1 —Ar—O—R 2 —O—R 3 —;

R 1 is alkyl containing 1-15 carbon atoms,

R 2 and R 3 are independently lower alkylene, and

X is a counter ion.

8. A pharmaceutical composition for topical application comprising a pharmaceutically effective amount of a drug and the carrier composition of claim 7 .

9. The pharmaceutical composition according to claim 7 wherein the drug and the carrier are present in a molar ratio of drug to carrier of greater than about 20.

10. The pharmaceutical composition according to claim 8 wherein the drug and the carrier are present in a molar ratio of between about 5 and about 20.

11. A method for treating skin sores, chapping, chafing, skin bruises or wounds on a mammal which comprises applying to the locus of the skin injury a pharmaceutical composition comprising a pharmaceutically effective amount of a drug and a skin penetrating effective amount of a carrier composition comprised of a compound having the formula selected from the group consisting of

wherein R 100 is fatty groups having 11-29 carbon atoms and R 101 and R 102 are independently a fatty group having 12-30 carbon atoms.

12. The pharmaceutical composition according to claim 11 wherein the drug and the carrier are present in a molar ratio of drug to carrier ranging from between about 5 to about 20.

13. A composition comprising a compound having the formula selected from the group consisting of

wherein R 100 is fatty groups having 11-29 carbon atoms and R 101 and R 102 are independently a fatty group having 12-30 carbon atoms and a tertiary amide of the formula

or pharmaceutically acceptable salts thereof,

wherein R 4 is a fatty group of 11-29 carbon atoms;

R 5 and R 6 are independently lower alkyl, aryl, aryl lower alkyl, or fatty group containing 11-29 carbon atoms or R 7 ;

R 7 is

R 1 —Ar—O—R 2 —O—R 3 —;

R 2 and R 3 are independently lower alkylene groups containing 1-6 carbon atoms,

R 1 is a lower alkyl, and

Ar is aryl.

14. The composition according to claim 13 additionally comprising nutrients and antioxidants.

15. The composition according to claim 13 wherein R 4 is a fatty group containing 15-21 carbon atoms.

16. The composition according to claim 15 wherein R 5 is aryl or aryl lower alkyl; and R 6 is

R 1 —Ar—O—R 2 —O—R 3 —;

R 2 and R 3 are independently alkylene containing 1-3 carbon atoms; and

Ar is aryl.

17. The composition according to claim 16 wherein Ar is phenyl.

18. The composition according to claim 17 wherein R 5 is aryl lower alkyl.

19. The composition according to claim 18 wherein R 5 is benzyl.

20. The composition according to claim 18 wherein R 4 is saturated.

21. The composition according to claim 19 wherein R 4 is unsaturated.

22. The composition according to claim 21 wherein R 4 contains 1-8 carbon-carbon double bonds.

23. The composition according to claim 13 wherein the tertiary amide is distearyl stearamide, distearyl linoleamide,

24. A composition comprising a compound having the formula selected from the group consisting of

wherein R 100 is fatty groups having 11-29 carbon atoms and R 101 and R 102 are independently a fatty group having 12-30 carbon atoms and a tertiary amide hydrate, wherein, the tertiay amide has the formula

or pharmaceutically acceptable salts thereof wherein

R 4 is a fatty group of 11-29 carbon atoms;

R 5 and R 6 are independently lower alkyl, aryl, aryl lower alkyl, or fatty group containing 11-29 carbon atoms or R 7 ;

R 7 is

R 1 —Ar—O—R 2 —O—R 3 —;

R 2 and R 3 are independently alkylene groups containing 1-6 carbon atoms;

R 1 is an alkyl group containing 1-15 carbon atoms; and

Ar is aryl;

said fatty group being either completely saturated or containing 1-8 carbon-carbon double bonds.

25. The composition of claims 24 wherein R 4 is a fatty group containing 15-21 carbon atoms.

26. The composition of claim 24 wherein R 5 is aryl or aryl lower alkyl; and R 6 is

R 1 —Ar—O—R 2 —O—R 3 —;

R 2 and R 3 are independently alkylene containing 1-3 carbon atoms; and

Ar is aryl.

27. The composition of claim 26 wherein Ar is phenyl.

28. The composition of claim 27 wherein R 5 is aryl lower alkyl.

29. The composition according to claim 28 wherein R 5 is benzyl.

30. The composition according to claim 28 wherein R 4 is saturated.

31. The composition according to claim 28 wherein R 4 is unsaturated.

32. The composition according to claim 28 wherein R 4 contains 1-8 carbon-carbon double bonds.

33. The composition according to claim 24 wherein the tertiary amide of the tertiary amide hydrate is selected from the group consisting of distearyl stearamide, distearyl linoleamide,

34. The composition according to claim 13 wherein the compound has the formula

wherein R 100 is fatty group containing 13 carbon atoms and R 102 is fatty group containing 16 carbon atoms.

35. The composition according to claim 24 wherein the compound has the formula

wherein R 100 is fatty group containing 13 carbon atoms and R 102 is an alkyl group containing 16 carbon atoms.

36. The composition according to claim 13 wherein the compound has the formula

37. The composition according to claim 24 wherein the compound has the formula

38. A compound having the formula

wherein R 100 is a fatty group having 11, 12, 14, 15, 16, 17 and 19-29 atoms and R 102 contains 12-15, 17, 19-30 atoms.

39. A carrier composition compound of claim 38 .

40. A compound having the formula

wherein R 100 is a fatty group having 11-15 and 17-29 carbon atoms and R 101 is a fatty group having 12-15 and 17-30 carbon atoms.

41. A carrier composition comprising the compound of claim 40 .

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2019
From: MICRODERMIS CORPORATION
To: HOSLER, JAMES P.
Reel/Frame 050005/0815 →
SECURITY INTEREST Recorded Jan 5, 2017
From: MICRODERMIS CORPORATION
To: HOSLER, JAMES, DR.
Reel/Frame 040862/0683 →
SECURITY INTEREST Recorded Dec 2, 2015
From: MICRODERMIS CORPORATION
To: CLARK, MICHAEL R.
Reel/Frame 037193/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2015
From: BETTLE, GRISCOM, III
To: DOCTORS SOLUTIONS, LLC
Reel/Frame 036603/0554 →
CHANGE OF NAME Recorded Sep 18, 2015
From: DOCTORS SOLUTIONS, LLC
To: DRSS GLOBAL, LLC
Reel/Frame 036640/0487 →
CHANGE OF NAME Recorded Sep 18, 2015
From: DRSS GLOBAL, LLC
To: MICRODERMIS CORPORATION
Reel/Frame 036640/0491 →
Continuity (3)
Division 10670034 · Sep 22, 2003
Provisional Application 60412437 · Sep 20, 2002
Related Publication 20100203005A1 · Aug 12, 2010